98 related articles for article (PubMed ID: 12039896)
1. In vitro evaluation of AZD2563, a new oxazolidinone, tested against beta-haemolytic and viridans group streptococci.
Anderegg TR; Biedenbach DJ; Jones RN
J Antimicrob Chemother; 2002 Jun; 49(6):1019-21. PubMed ID: 12039896
[TBL] [Abstract][Full Text] [Related]
2. Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with nine other agents.
Peric M; Lin G; Clark CL; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2002 Jul; 50(1):95-100. PubMed ID: 12096012
[TBL] [Abstract][Full Text] [Related]
3. Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone.
Anderegg TR; Jones RN
Int J Antimicrob Agents; 2004 Jan; 23(1):6-10. PubMed ID: 14732307
[TBL] [Abstract][Full Text] [Related]
4. AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains.
Jones RN; Anderegg TR; Deshpande LM
Diagn Microbiol Infect Dis; 2002 May; 43(1):87-90. PubMed ID: 12052634
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility testing of Streptococcus pneumoniae and Viridans streptococcal isolates against: quinolones, oxazolidinones and glycopeptides.
Băncescu G; Neagu AS; Radu-Popescu M; Nica M; Dascălu A; Nistor I; Bărbuceanu SF; Băncescu A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(1):286-90. PubMed ID: 23077910
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocci.
Fluit AC; Schmitz FJ; Verhoef J; Milatovic D
J Antimicrob Chemother; 2002 Aug; 50(2):271-6. PubMed ID: 12161411
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual gram-positive species.
Jones RN; Biedenbach DJ; Anderegg TR
Diagn Microbiol Infect Dis; 2002 Feb; 42(2):119-22. PubMed ID: 11858907
[TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates.
Anderegg TR; Biedenbach DJ; Jones RN
Antimicrob Agents Chemother; 2002 Aug; 46(8):2662-4. PubMed ID: 12121951
[TBL] [Abstract][Full Text] [Related]
9. Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents.
Ednie LM; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2002 Jul; 50(1):101-5. PubMed ID: 12096013
[TBL] [Abstract][Full Text] [Related]
10. Distribution of tetracycline resistance genes tet(M), tet(O), tet(L) and tet(K) in blood isolates of viridans group streptococci harbouring erm(B) and mef(A) genes. Susceptibility to quinupristin/dalfopristin and linezolid.
Rodriguez-Avial I; Rodriguez-Avial C; Culebras E; Picazo JJ
Int J Antimicrob Agents; 2003 Jun; 21(6):536-41. PubMed ID: 12791466
[TBL] [Abstract][Full Text] [Related]
11. Activity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid.
Howe RA; Wootton M; Noel AR; Bowker KE; Walsh TR; MacGowan AP
Antimicrob Agents Chemother; 2003 Nov; 47(11):3651-2. PubMed ID: 14576139
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci.
Johnson AP; Warner M; Livermore DM
J Antimicrob Chemother; 2002 Jul; 50(1):89-93. PubMed ID: 12096011
[TBL] [Abstract][Full Text] [Related]
13. Comparative activities of the oxazolidinone AZD2563 and linezolid against selected recent North American isolates of Streptococcus pneumoniae.
Baum SE; Crawford SA; McElmeel ML; Whitney CG; Jorgensen JH
Antimicrob Agents Chemother; 2002 Sep; 46(9):3094-5. PubMed ID: 12183281
[TBL] [Abstract][Full Text] [Related]
14. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program.
Mutnick AH; Enne V; Jones RN
Ann Pharmacother; 2003 Jun; 37(6):769-74. PubMed ID: 12773059
[TBL] [Abstract][Full Text] [Related]
15. Effects of tigecycline, linezolid and vancomycin on biofilms of viridans streptococci isolates from patients with endocarditis.
Presterl E; Lassnigg A; Eder M; Reichmann S; Hirschl AM; Graninger W
Int J Artif Organs; 2007 Sep; 30(9):798-804. PubMed ID: 17918125
[TBL] [Abstract][Full Text] [Related]
16. AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro.
Wookey A; Turner PJ; Greenhalgh JM; Eastwood M; Clarke J; Sefton C
Clin Microbiol Infect; 2004 Mar; 10(3):247-54. PubMed ID: 15008947
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of the new oxazolidinone AZD2563 against Enterococci.
Eliopoulos GM; Wennersten CB; Moellering RC
Antimicrob Agents Chemother; 2002 Oct; 46(10):3273-5. PubMed ID: 12234858
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of viridans group streptococci isolated from blood in southwest Finland in 1993-2004.
Lindgren M; Jalava J; Rantakokko-Jalava K; Meurman O
Scand J Infect Dis; 2007; 39(6-7):508-13. PubMed ID: 17577811
[TBL] [Abstract][Full Text] [Related]
19. Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis.
Kosowska-Shick K; Smith K; Bogdanovich T; Ednie LM; Jones RN; Appelbaum PC
Antimicrob Agents Chemother; 2006 Dec; 50(12):4191-4. PubMed ID: 17043120
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of linezolid, meropenem, and quinupristin-dalfopristin against group C and G streptococci, including vancomycin-tolerant isolates.
Zaoutis T; Moore LS; Furness K; Klein JD
Antimicrob Agents Chemother; 2001 Jul; 45(7):1952-4. PubMed ID: 11408207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
